Angion was founded in 1998 by Dr. Itzhak Goldberg. From our incorporation through 2014, our efforts were primarily focused on researching a number of pathways related to serious organ diseases and applying our medicinal chemistry expertise towards creating potential therapeutics to address the unmet medical needs of patients. Our lead program, ANG-3070, entered Phase 1 in late 2019 and we reported positive data from that trial in early 2021. ANG-3070 is now in a Phase 2 trial in patients with primary proteinuric disease and we intend to start a second Phase 2 trial of ANG-3070 in patients with idiopathic pulmonary fibrosis.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
- Year Founded:
Who We Are
Angion is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries.
The Angion team is dedicated to bring new therapeutic options to patients. Currently our primary focus is chronic fibrotic conditions in the lung and kidney where effective treatments with more limited off-target toxicities are needed.